History and Evolution of Clinical Research Regulation in India – Recent Reforms and Current Landscape

This article is an extension of our earlier discussion on the evolution of clinical research regulation in India, where we examined developments from the colonial era through the emergence of structured clinical trial governance in the early 2000s. In this continuation, we briefly recap the earlier regulatory foundations and focus on the major reforms that reshaped the modern clinical research ecosystem in India.

Brief Recap: Foundations of Clinical Research Regulation in India

India’s regulatory journey began with basic drug control laws aimed at ensuring quality and safety of medicines. Key milestones included:

• Poisons Act, 1919 regulating toxic substances

• Dangerous Drugs Act, 1930 controlling narcotic drugs

• Drugs and Cosmetics Act, 1940 establishing structured drug regulation

• Formation of CDSCO and office of DCGI

• Indian Patents Act, 1970 enabling growth of domestic pharmaceutical industry

• TRIPS agreement and product patent regime (2005)

• ICMR Ethical Guidelines (2000)

• Indian GCP Guidelines (2001)

• Revised Schedule Y (2005) defining clinical trial requirements

These developments positioned India as an emerging hub for global clinical trials. However, rapid growth also exposed gaps in regulatory oversight and ethical governance.

Rapid Growth and Emerging Concerns (2008–2011)

With increasing global trials in India, concerns began to emerge related to:

• Inadequate informed consent

• Ethical conduct of trials

• Compensation for trial-related injury

• Oversight of investigators and CROs

• Monitoring of clinical trial sites

These concerns triggered regulatory scrutiny and eventually led to judicial intervention.

Regulatory Reform Phase (2011–2015)

Following observations by the Supreme Court of India, regulatory authorities introduced a series of reforms to strengthen participant protection and improve oversight.

Key Regulatory Measures

Ethics Committee Registration: All Ethics Committees were mandated to register with DCGI to ensure accountability and uniform standards.

Compensation Framework: Clear guidelines were introduced for compensation in case of trial-related injury or death.

Audiovisual Informed Consent: To improve transparency, audiovisual recording of informed consent was mandated in specific scenarios.

Investigator Oversight: Limitations were placed on the number of trials per investigator to maintain quality and oversight.

Enhanced Safety Reporting: Strengthened pharmacovigilance and safety reporting requirements were introduced.

Structural Changes in Regulatory Review

The regulatory review process was also restructured:

• New Drug Advisory Committees replaced by Subject Expert Committees (SEC)

• Introduction of Technical Review Committee (TRC)

• Increased scrutiny of clinical trial applications

• Strengthened regulatory decision-making process

Although these changes temporarily slowed approvals, they significantly improved credibility and regulatory confidence.

Transition to Modern Regulatory Framework (2016–Present)

Following the reform phase, India focused on creating a balanced ecosystem that promotes innovation while ensuring patient safety.

New Drugs and Clinical Trials Rules (NDCTR), 2019

This landmark reform introduced:

• Defined timelines for approvals (30–90 days)

• Deemed approval provisions

• Simplified academic clinical trial process

• Clear compensation and medical management rules

• Post-trial access provisions

• Support for orphan drugs and accelerated approvals

NDCTR 2019 significantly improved predictability and transparency.

Digitalization and Transparency

Regulatory modernization included:

• Launch of SUGAM portal for online submissions

• Mandatory CTRI registration

• Online tracking of approvals

• Improved regulatory transparency

These initiatives reduced timelines and improved efficiency.

Focus on Innovation and Emerging Therapies

Recent regulatory initiatives support innovation in:

• Biologics and biosimilars

• Vaccines and advanced therapies

• Emergency approvals (e.g., pandemic response)

• Indigenous R&D and Make in India initiatives

Global Alignment of Indian Regulations

India’s regulatory framework is now aligned with:

• ICH-GCP standards

• Global ethical guidelines

• International pharmacovigilance practices

• Harmonized clinical trial requirements

This alignment supports global multi-country trials.

Current Scenario: A Balanced Clinical Research Ecosystem

Today, India offers:

• Structured and predictable regulatory pathways

• Strong ethical oversight

• Defined approval timelines

• Transparent regulatory processes

• Globally competitive clinical research environment

India has regained its position as a preferred destination for clinical trials.

Conclusion

The evolution of clinical research regulation in India reflects a transition from basic drug control to a comprehensive and globally harmonized regulatory system. While earlier phases revealed regulatory gaps and ethical concerns, reforms between 2011 and 2019 significantly strengthened oversight and participant protection.

Regulation remains a dynamic process. As new technologies, real-world evidence, and innovative therapies emerge, Indian regulators will continue adapting — ensuring patient safety, ethical integrity, and scientific excellence remain at the core of clinical research.

Related Insights

1. CDSCO Approval Process for Clinical Trials in India: Complete Guide
2. History of Clinical Research Regulation in India
3. What is a CRO? Role of Clinical Research Organizations in India
4. Clinical Trial Process in India: Step-by-Step Guide